Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolism and disposition of imatinib mesylate in healthy volunteers.

Drug metabolism and disposition: the biological fate of chemicals - 1 Oct 2005

Gschwind Hans-Peter, Pfaar Ulrike, Waldmeier Felix, Zollinger Markus, Sayer Claudia, Zbinden Peter, Hayes Michael, Pokorny Rolf, Seiberling Michael, Ben-Am Monique, Peng Bin, Gross Gerhard

Abstract excerpt

Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of (14)C-labeled imatinib mesylate....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, Liquid

Share to Cytochrome P-450 CYP2D6

Share to Imatinib Mesylate

Share to Mass Spectrometry

Share to Piperazines

Share to Pyrimidines

Source

Identifiers

PMID: 16006570
DOI: 10.1124/dmd.105.004283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Metabolism and disposition of imatinib mesylate in healthy volunteers.PMID 16006570Read ↗

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Semantic proximity Read ↗

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.Semantic proximity Read ↗

Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells.Semantic proximity Read ↗

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.Semantic proximity Read ↗

Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib Penetration into Liver Metastases of Gastrointestinal Stromal TumorsSemantic proximity Read ↗

ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.Semantic proximity Read ↗

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.Semantic proximity Read ↗

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.Semantic proximity Read ↗

Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.